Global Necrotising Enterocolitis Market to Reach USD 7,301.50 Million by 2032 | CAGR of 5.3%
Category : Aerospace and Defence | Published Date : Jan 2025 | Type : Press Release
Necrotising Enterocolitis Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Necrotising Enterocolitis Market was valued at USD 4,830.65 million in 2024 and is projected to grow at a CAGR of 5.3%, reaching USD 7,301.50 million by 2032. Necrotising enterocolitis (NEC) is a severe gastrointestinal condition primarily affecting premature infants, characterized by intestinal inflammation and necrosis. Key advancements in diagnostic tools, nutritional support, and therapeutic interventions are driving market growth. These solutions aim to improve neonatal survival, reduce complications, and enhance healthcare outcomes.
The report comprises the Necrotising Enterocolitis Market Share, Size & Industry Analysis, based on Stage (Stage I (Suspected NEC), Stage II (Definite NEC), Stage III (Advanced NEC)), Treatment (Medications (Antibiotics, Analgesics, Probiotics), Surgery (Bowel Resection, Drainage Procedures)), Diagnosis (Laboratory Tests (Blood Tests, Stool Tests), Imaging Techniques (X-rays, Ultrasound, CT Scans)), End-User (Hospitals, Neonatal Intensive Care Units (NICUs), Specialty Clinics), and Region (North America, Europe, Asia-Pacific, Middle East & Africa, Latin America), and Forecast, 2025-2032.
The report contains detailed information on Necrotising Enterocolitis Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Segmental Analysis :
Based on stage, the market is segmented into Stage I (Suspected NEC), Stage II (Definite NEC), and Stage III (Advanced NEC).
- The Stage I segment accounted for the largest revenue share of 38.60% in 2024, driven by early diagnosis and preventive care measures that reduce disease progression and improve neonatal outcomes.
- The Stage III segment is anticipated to grow at the fastest rate, fueled by advancements in surgical interventions and the increasing prevalence of severe NEC cases requiring specialized care.
Based on treatment, the market is segmented into Medications (Antibiotics, Analgesics, Probiotics) and Surgery (Bowel Resection, Drainage Procedures).
- The medications segment dominated the market in 2024, attributed to the efficacy of antibiotics in infection management and probiotics in preventing NEC among high-risk neonates.
- The surgery segment is projected to grow at the fastest CAGR, supported by innovations in minimally invasive techniques and enhanced post-operative care in NICUs.
Based on diagnosis, the market is segmented into Laboratory Tests (Blood Tests, Stool Tests) and Imaging Techniques (X-rays, Ultrasound, CT Scans).
- The imaging techniques segment accounted for the largest revenue share in 2024, owing to their critical role in accurate diagnosis and disease monitoring through advanced imaging tools like X-rays and ultrasounds.
- The laboratory tests segment is expected to grow at the fastest rate, driven by non-invasive diagnostic advancements and the rising adoption of biomarker-based testing methods.
Based on end-user, the market is segmented into Hospitals, Neonatal Intensive Care Units (NICUs), and Specialty Clinics.
- The hospitals segment held the largest revenue share in 2024, supported by the availability of advanced diagnostic tools and multidisciplinary care teams.
- The NICUs segment is expected to grow at the fastest rate, driven by increased investments in neonatal healthcare infrastructure and advancements in monitoring systems.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America: Dominated the market in 2024 with a valuation of USD 1,602.37 million, attributed to advanced healthcare infrastructure and high neonatal care standards.
- Asia-Pacific: Expected to grow at the fastest CAGR of 5.7%, driven by improving healthcare infrastructure and rising awareness of neonatal health in countries like China and India.
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 7,301.50 Million |
| CAGR (2025-2032) | 5.3% |
| Stage | Stage I (Suspected NEC), Stage II (Definite NEC), Stage III (Advanced NEC) |
| Treatment | Medications (Antibiotics, Analgesics, Probiotics), Surgery (Bowel Resection, Drainage Procedures) |
| Diagnosis | Laboratory Tests (Blood Tests, Stool Tests), Imaging Techniques (X-rays, Ultrasound, CT Scans) |
| End-User | Hospitals, NICUs, Specialty Clinics |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Necrotising Enterocolitis Industry:
- Abbott Laboratories (United States)
- Nestlé S.A. (Switzerland)
- Danone S.A. (France)
- Mead Johnson Nutrition Company (United States)
- Fresenius Kabi AG (Germany)
- Prolacta Bioscience, Inc. (United States)
- Hollister Incorporated (United States)
- Baxter International Inc. (United States)
- Royal Philips N.V. (Netherlands)
- GE Healthcare (United States)
Recent Industry Developments :
- June 2024: Prolacta Bioscience launched an advanced human milk-based fortifier designed to support gut health and reduce the risk of NEC in premature infants.
